Use of a sodium--glucose cotransporter 2 inhibitor, empagliflozin, in a patient with Rabson-Mendehall Syndrome

Rabson-Mendenhall Syndrome (RMS) is a rare condition caused by mutations in the insulin receptor gene. The affected patients have severe insulin resistance and the treatment is challenging due to difficulties in reaching satisfactory glycemic control. We report a case where iSGT2 was used as an adjunct therapy to insulin.